RxDoctor Payments Data

Keata Bhakta

Acute Care · Chandler, AZNPI 1073059655

Payments from drug & device makers

$2,308in general payments, 2019–2025

Across 86 payments — averaging $26.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$492
  • Collegium Pharmaceutical, Inc.$361
  • Nevro Corp.$324
  • Nalu Medical, Inc.$316
  • Globus Medical$262
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$153
  • plus $400 from 10 others

What the payments were for

  • Food & beverage$2,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,308 in reported general payments places this provider in the 75th percentile of 482 acute care providers in Arizona.

See all acute care providers in Arizona

Medicare billing

Part B allowed, 2024
$133,446
Medicare patients
196
Services billed
1,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate41$26,997
BelbucaBuprenorphine Hcl30$22,838
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen259$8,869
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen247$6,607
Buprenorphine29$6,466
Gabapentin366$4,649
Oxycodone Hcl258$3,594
Pregabalin144$3,169
Naloxone Hcl44$2,530
Tizanidine Hcl175$2,274
Methocarbamol91$1,667
Duloxetine Hcl65$1,614
Tramadol Hcl51$1,266
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine14$1,257
Lidocaine-PrilocaineLidocaine/Prilocaine24$1,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$361$49,83471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 482 acute care providers in Arizona.

Other acute care in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →